Proactive One2One Investor Forum

AI SummaryClose X

Coiled Therapeutics plc announced its participation in the Proactive One2One Investor Forum in London on June 24, 2026, where Chairman Sotirios Stergiopoulos will present. The company, listed on AIM and OTCQB, is developing precision medicines for hard-to-treat cancers, with its lead program AO-252, a TACC3 inhibitor, currently in Phase I clinical trials in the USA. The presentation will be available on the company's website, and investors can register for the event online.

Disclaimer*

UK 100

Latest directors dealings